STOCKSCOUTER
StockScouter Premium
StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance
Learn more or Get it now! Stockscouter Portfolio performance
MYGN MYRIAD GENETICS INCORPORATED StockScouter® Report
7
StockScouter® Score
MYRIAD GENETICS INCORPORATED, a small cap growth company in the healthcare sector, is expected to outperform the market over the next six months with slightly less than average risk
10 is the best possible rating. Learn more.
Summary
Positives
- The most recent quarterly earnings report was significantly higher than analysts’ consensus forecast. Positive
- Moving average analysis for MYGN suggests upward price movement over the medium term. Positive
Concerns
- Short-term relative price momentum exhibits meaningful weakness. Negative
- The multi-period measure of relative price change and consistency is below average. Negative/Neutral
Short-term Outlook
Over the next 1-2 months, StockScouter forecasts that small cap stocks will be neutral, growth stocks will be neutral, and healthcare stocks will be neutral.
Expected Risk/Return
Core Model Grades
A
C
C
D